ORIGINAL ARTICLEEthnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry
Section snippets
PATIENTS AND METHODS
A detailed description of the study design, methodology, and baseline characteristics of individuals enrolled in the international, prospective REACH Registry has been previously reported.1, 8 Briefly, the registry included outpatients aged 45 years or older with either established atherothrombotic disease (CAD, PAD, or CVD) or 3 or more cardiovascular risk factors from 5587 practices in 44 countries. Study participants were enrolled from December 1, 2003, to June 30, 2004 (except in Japan,
RESULTS
Overall, 49,602 outpatients in the REACH Registry with established atherothrombotic disease at baseline were included in this analysis. At 2 years, 45,191 individuals (91%) were available for follow-up. A total of 747 participants (1.5%) died within the first 2 years, and 3664 (7%) were lost to follow-up at 2 years. The rate of lost to follow-up varied among the ethnic/racial groups: from 3% in East Asians to 16% in blacks. Baseline demographics, including atherosclerotic disease, risk factors,
DISCUSSION
The results of this wide-reaching, contemporary analysis composed of a markedly diverse population with stable CAD, CVD, and/or PAD demonstrate important ethnic-specific variations in the risks, management, and outcomes associated with atherothrombotic disease. Blacks with atherothrombotic disease, mainly comprising African Americans from the United States (95%), had the highest rate of cardiovascular death among the ethnic/racial groups worldwide. In contrast, Asians had significantly lower
CONCLUSION
Our findings from this large global registry of individuals with atherothrombotic disease illustrate several important ethnic differences in treatment patterns and outcomes from the current era. In general, blacks (consisting mainly of African Americans) had higher rates of adverse cardiovascular outcomes, with the highest rate of cardiovascular death among the groups. However, Asians had significantly lower rates of all-cause and cardiovascular death. The underlying etiologies for these
REFERENCES (20)
- et al.
Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study
Lancet
(2008) - et al.
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
Am Heart J
(2009) - et al.
Disparities in cardiac care: rising to the challenge of Healthy People 2010
J Am Coll Cardiol
(2004) - et al.
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
Am Heart J
(2006) - et al.
Corrected group prognostic curves and summary statistics
J Chronic Dis
(1982) - et al.
High frequency of cardiovascular risk factors in overweight adult Japanese subjects
Arch Med Res
(2007) - et al.
Outcomes in African Americans and whites after percutaneous coronary intervention
Am J Med
(2005) - et al.
Disparities in the treatment and outcomes of vascular disease in Hispanic patients
J Vasc Surg
(2007) - et al.
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Am Heart J
(2009) - et al.
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
JAMA
(2006)
Cited by (84)
Breast arterial calcification rates in a diverse, urban group of screening mammography patients
2022, Annals of EpidemiologyPathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants
2022, Genes and DiseasesCitation Excerpt :While these genes potentially play a pathogenetic role in CAD, the underlying mechanisms remain to be elucidated. Most findings of CAD-related genetic variants are from studies conducted in European populations; however, ethnicity is an important risk factor that may be involved in the pathogenesis of PCAD.60 Due to genetic heterogeneity, CAD-related SNPs identified in populations with European ancestry may not be related to CAD in other ancestral populations.61
Benefits of statin therapy within a year after kidney transplantation
2024, Scientific ReportsEvaluating the Cardiovascular Impact of Genetically Proxied PCSK9 and HMGCR Inhibition in East Asian and European Populations: A Drug-Target Mendelian Randomization Study
2024, Circulation: Genomic and Precision Medicine
A complete list of the REACH Registry investigators is published in JAMA. 2006;295(2):180-189.
We thank sanofi-aventis and Bristol-Myers Squibb for their support of the REACH Registry. The REACH Registry is endorsed by the World Heart Federation. The sponsor was able to review the manuscript before submission but did not have the authority to change any aspect of the manuscript.
Individual reprints of this article are not available.
- 1
Dr Bhatt has received institutional research support from AstraZeneca, Bristol- Myers Squibb, Eisai, Ethicon, Medtronic, sanofi-aventis, and The Medicines Company.
- 2
Dr Gersh is a member (<3 years) of the advisory boards of Bristol-Myers Squibb, Boston Scientific, Amorcyte Inc, Merck, Cardiovascular Therapeutics, and AstraZeneca.
- 3
Dr Röther has received honoraria and consulting fees from sanofiaventis, Bristol-Myers Squibb, Lundbeck, and Boehringer Ingelheim.
- 4
Dr Goto has received honoraria and consulting fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Kowa, Novartis, Otsuka, sanofi-aventis, Schering-Plough, and Takeda, and he has received research grants from Eisai, Ono, sanofi-aventis, AstraZeneca, Kowa, and Pfizer.
- 5
Dr Wilson has received grant support from sanofi-aventis.
- 6
Dr Salette is an employee of sanofi-aventis.
- 7
Dr Steg has received research grants from sanofi-aventis and has been either a speaker or a consultant for Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Endotis, GlaxoSmithKline, Medtronic, MSD, Nycomed, sanofi-aventis, Servier, and The Medicines Company.